Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.

Abstract

Chemotherapy-associated interstitial lung disease (ILD) is often fatal, and the chemotherapeutic regimen generally cannot be resumed. ILD associated with the mammalian target of rapamycin (mTOR) inhibitor everolimus has many features distinct from chemotherapy-associated ILD. We present the case of a 58-year-old woman with an advanced pancreatic neuroendocrine tumor with liver metastases, in whom everolimus treatment was maintained and resulted in a partial response despite two occurrences of everolimus-induced ILD during a 31-month treatment period until disease progression. Physicians treating with everolimus should monitor patients closely for ILD and should apply appropriate management strategies to optimize the possibility of maintaining everolimus therapy.

• Authors: Yusuke Nakayama, Masafumi Ikeda, Motohiro Kojima, Koichi Goto, Miyuki Hara, Hiroyuki Okuyama, Hideaki Takahashi, Izumi Ohno, Satoshi Shimizu, Shuichi Mitsunaga, Takuji Okusaka
• Journal: Chemotherapy (Chemotherapy) Vol. 59 Issue 1 Pg. 74-8 ( 2013) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 23867634 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 S. Karger AG, Basel.

Chemical References

• Antineoplastic Agents
• MUC1 protein, human
• Mucin-1
• C-Reactive Protein
• Everolimus
• Sirolimus

Topics

• Antineoplastic Agents (therapeutic use)
• C-Reactive Protein (analysis)
• Everolimus
• Female
• Humans
• Liver Neoplasms (pathology, secondary)
• Lung Diseases, Interstitial (chemically induced, diagnostic imaging, metabolism)
• Middle Aged
• Mucin-1 (blood)
• Neoplasm Staging
• Neuroendocrine Tumors (drug therapy)
• Pancreatic Neoplasms (drug therapy)
• Sirolimus (analogs & derivatives, therapeutic use)
• Tomography, X-Ray Computed